Literature DB >> 27449344

Survival of Patients with Advanced Non-Small Cell Lung Cancer Enrolled in Clinical Trials.

Oscar Arrieta1, Amir Carmona, Laura Alejandra Ramírez-Tirado, Diana Flores-Estrada, Eleazar Omar Macedo-Pérez, Jorge Negueb Martínez-Hernández, José Francisco Corona-Cruz, Andrés F Cardona, Jaime de la Garza.   

Abstract

BACKGROUND: Up-to-date oncological therapy has been accomplished through the results of clinical trials (CTs). We analyzed the overall survival (OS) of patients with non-small cell lung cancer (NSCLC) and its relation to CT enrollment.
METHODS: The study included 1,042 patients with advanced NSCLC treated at the Instituto Nacional de Cancerología. All patients received treatment according to the national and international guidelines. Data were collected from medical records. Patients were subgrouped on the basis of their CT enrollment as follows: participants in any CT (ACT), exclusively intervention CTs (ICT) or exclusively pharmaceutical-sponsored CTs (PCT).
RESULTS: The CT enrollment effect was assessed through a multivariate Cox proportional hazards model. Thirty percent of the patients were in ACT, 28.3% in ICT and 13.7% in PCT. Female gender (p = 0.001), adenocarcinoma histology (p = 0.018), positive EGFR mutation (p = 0.006), and better ECOG performance status (<2) (p ≤ 0.0001) were more frequent in patients enrolled in CT; further, tobacco smoking (p ≤ 0.0001) and KRAS mutation (p = 0.001) were more frequent in patients who were not enrolled in a CT.
CONCLUSION: Enrollment in ACT was associated with a better OS (hazard ratio: 0.47-0.74). NSCLC patients enrolled in a CT have an improved survival in an independent manner to other prognostic factors.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27449344     DOI: 10.1159/000447404

Source DB:  PubMed          Journal:  Oncology        ISSN: 0030-2414            Impact factor:   2.935


  9 in total

1.  Oridonin enhances the radiosensitivity of lung cancer cells by upregulating Bax and downregulating Bcl-2.

Authors:  Sirui Li; Dan Shi; Liangyu Zhang; Fang Yang; Guanghui Cheng
Journal:  Exp Ther Med       Date:  2018-09-27       Impact factor: 2.447

2.  Factors associated with enrolment in clinical trials among women with early-stage breast cancer.

Authors:  D Presti; J Havas; D Soldato; P Lapidari; E Martin; B Pistilli; C Jouannaud; G Emile; O Rigal; M Fournier; P Soulie; M-A Mouret-Reynier; C Tarpin; M Campone; S Guillermet; A-L Martin; S Everhard; A Di Meglio
Journal:  ESMO Open       Date:  2022-06-17

3.  Quantifying geographical accessibility to cancer clinical trials in different income landscapes.

Authors:  G Tini; D Trapani; B A Duso; P Beria; G Curigliano; P G Pelicci; L Mazzarella
Journal:  ESMO Open       Date:  2022-06-21

Review 4.  Testing for EGFR Mutations and ALK Rearrangements in Advanced Non-Small-Cell Lung Cancer: Considerations for Countries in Emerging Markets.

Authors:  Mercedes L Dalurzo; Alejandro Avilés-Salas; Fernando Augusto Soares; Yingyong Hou; Yuan Li; Anna Stroganova; Büge Öz; Arif Abdillah; Hui Wan; Yoon-La Choi
Journal:  Onco Targets Ther       Date:  2021-09-01       Impact factor: 4.345

5.  The effect of nabilone on appetite, nutritional status, and quality of life in lung cancer patients: a randomized, double-blind clinical trial.

Authors:  Jenny G Turcott; María Del Rocío Guillen Núñez; Diana Flores-Estrada; Luis F Oñate-Ocaña; Zyanya Lucia Zatarain-Barrón; Feliciano Barrón; Oscar Arrieta
Journal:  Support Care Cancer       Date:  2018-03-17       Impact factor: 3.603

6.  Targeted next generation sequencing identified a high frequency genetic mutated profile in wood smoke exposure-related lung adenocarcinoma patients.

Authors:  Giovanny Soca-Chafre; Norma Hernández-Pedro; Alejandro Aviles-Salas; Carmen Alaez Versón; Karol Carrillo Sánchez; Andrés F Cardona; Federico Avila-Moreno; Pedro Barrios-Bernal; Diana Flores-Estrada; Oscar Arrieta
Journal:  Oncotarget       Date:  2018-07-17

7.  Are cancer patients better off if they participate in clinical trials? A mixed methods study.

Authors:  Zandra Engelbak Nielsen; Stefan Eriksson; Laurine Bente Schram Harsløf; Suzanne Petri; Gert Helgesson; Margrete Mangset; Tove E Godskesen
Journal:  BMC Cancer       Date:  2020-05-08       Impact factor: 4.430

8.  STRA6 Polymorphisms Are Associated With EGFR Mutations in Locally-Advanced and Metastatic Non-Small Cell Lung Cancer Patients.

Authors:  Saé Muñiz-Hernández; Jesús Bernardino Velázquez-Fernández; José Díaz-Chávez; Omar Mondragón-Fonseca; Yerye Mayén-Lobo; Alberto Ortega; Marisol López-López; Oscar Arrieta
Journal:  Front Oncol       Date:  2020-11-24       Impact factor: 6.244

9.  Lung Cancer Disparities in Hispanics: Molecular Diagnosis and Use of Immunotherapy.

Authors:  Luis E Raez; Andrés F Cardona; Oscar Arrieta; Gilberto Lopes
Journal:  JCO Glob Oncol       Date:  2020-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.